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Abstract
Background and Objective: High bilirubin/albumin (B/A) ratios increase the risk of bilirubin neurotoxicity. The B/A ratio may
be a valuable measure, in addition to the total serum bilirubin (TSB), in the management of hyperbilirubinemia. We aimed to
assess whether the additional use of B/A ratios in the management of hyperbilirubinemia in preterm infants improved
neurodevelopmental outcome.
Methods: In a prospective, randomized controlled trial, 615 preterm infants of 32 weeks’ gestation or less were randomly
assigned to treatment based on either B/A ratio and TSB thresholds (consensus-based), whichever threshold was crossed
first, or on the TSB thresholds only. The primary outcome was neurodevelopment at 18 to 24 months’ corrected age as
assessed with the Bayley Scales of Infant Development III by investigators unaware of treatment allocation. Secondary
outcomes included complications of preterm birth and death.
Results: Composite motor (100613 vs. 101612) and cognitive (101612 vs. 101611) scores did not differ between the B/A
ratio and TSB groups. Demographic characteristics, maximal TSB levels, B/A ratios, and other secondary outcomes were
similar. The rates of death and/or severe neurodevelopmental impairment for the B/A ratio versus TSB groups were 15.4%
versus 15.5% (P = 1.0) and 2.8% versus 1.4% (P = 0.62) for birth weights #1000 g and 1.8% versus 5.8% (P = 0.03) and 4.1%
versus 2.0% (P = 0.26) for birth weights of .1000 g.
Conclusions: The additional use of B/A ratio in the management of hyperbilirubinemia in preterm infants did not improve
their neurodevelopmental outcome.
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Background
Free bilirubin (Bf), i.e. the fraction of bilirubin not bound to
albumin, crosses the blood-brain barrier and exhibits neurotoxic-
ity. In accordance, the total bilirubin load together with Bf is
thought to predict bilirubin neurotoxicity more reliably than the
total serum bilirubin (TSB), as assessed by clinical and electro-
physiological parameters, i.e. neurodevelopmental outcome and
maturation of automated brain stem responses, respectively. [1–4]
Nevertheless, only TSB and not Bf is incorporated in the clinical
management of hyperbilirubinemia. Neither is it routine practice
to measure Bf in clinical laboratories nor are FDA approved
instruments commercially available. The bilirubin (TSB)/albumin
(B/A) ratio, which could be a surrogate for Bf, might be a good
additional parameter to TSB, to indicate an increased risk of
bilirubin-induced neurotoxicity in preterm infants. To date,
mainly retrospective data have favored an additional role for high
B/A ratios as risk factors for bilirubin-induced neurotoxicity and
only limited data exist regarding B/A ratios in the management
and neurodevelopmental outcome of preterm infants with
unconjugated hyperbilirubinemia. [5] What is lacking are
prospective clinical trials on the use of the B/A ratio in jaundiced
preterm infants to evaluate its safety and clinical utility in
preventing or reducing long-term bilirubin-induced neurotoxicity.
We conducted a prospective, multicenter, randomized con-
trolled trial on the management of preterm infants with
hyperbilirubinemia to determine the effects of the additional use
of B/A ratios on their neurodevelopmental outcome at 18 to 24
months after the expected date of delivery.
Methods
Patients
Preterm infants of 31+6 weeks’ gestation or less (based on the
first day of the last menstruation), were eligible for enrollment after
admission to a neonatal intensive care unit (NICU) during the first
24 hours after birth. Exclusion criteria were major congenital
malformations, clinical syndromes, or chromosomal abnormalities.
Ethics Statement
The Medical Ethics Review Board of the University Medical
Center Groningen, the Netherlands, and all ten Dutch NICUs
approved the study. Written informed consent was obtained from
the parents or guardian of each participating infant. This study
was conducted according to the principles expressed in the
Declaration of Helsinki. This study is registered in the ISRCTN
Register, number 74465643.
The protocol for this trial and supporting CONSORT checklist
and flowchart are available as supporting information (see
Checklist S1, Flowchart S1 and Protocol S1).
Randomisation and masking
Infants were stratified on the basis of center and gestational age
(24+0 to 28+6 and 29+0 to 31+6 weeks), and were randomly assigned
by neonatologists to a treatment group (balance [1:1]) by a
centralized computer system. Parents, care givers, and those
assessing the outcomes were blinded to group assignment.
Treatment
During the first ten days hyperbilirubinemia in infants in the B/
A ratio group was evaluated daily using the B/A ratio together
with TSB. Treatment decisions were based on the B/A ratio and
the TSB level, whichever threshold was crossed first. We chose to
use both thresholds in this study group because we considered the
evidence from previous studies, regarding the safety of B/A ratio
thresholds insufficient, to justify ignoring TSB thresholds.
TSB and albumin levels were also measured daily for infants in
the TSB group (control group), but treatment was based on the
TSB level only. TSB and albumin were measured using routine
analytical methods. [6]
The TSB treatment thresholds (in mmol/L) for phototherapy
(PT) and exchange transfusion were uniform and consensus-based.
The B/A ratio thresholds (in mmol/L divided by g/L= mmol/g)
were also uniform and derived from the corresponding TSB values
and albumin levels of 25 g/L and 30 g/L for infants with birth
weights of , or .1250 g, respectively. [7] Treatment nomograms
depended on infants’ birth weights and risk factors (see Figure
S1), and national guidelines for phototherapy and exchange
transfusions were available on line. [8]
Assessments
The primary outcome was the composite motor score at 18 to
24 months’ corrected age because previous retrospective data
analyses of the National Institute of Child Health and Human
Development (NICHD) Phototherapy Trial showed that peak
bilirubin levels correlated with psychomotor developmental indices
(PDI). [9] The 3rd Version of the Bayley Scales of Infant and
Toddler Development (BSID III) was used to assess fine and gross
motor as well as cognitive functions by investigators who were
unaware of the treatment allocations. Standardized, pediatric,
neurologic evaluations were performed at the same age as the
BSID III assessments. Cerebral palsy and mild neurological
dysfunction were diagnosed using international criteria and
definitions. [10] Hearing and vision were assessed with standard-
ized tests.
Secondary outcomes included death, neurodevelopmental
impairment (NDI), pre-defined clinical diagnoses, and potential
adverse events. Neurodevelopmental impairment was defined as a
composite motor score of ,85 or a composite mental score of
,85, any degree of cerebral palsy, any visual impairment, or any
hearing impairment. Severe NDI was defined as a composite
motor score of,70 or a composite mental score of,70, moderate
or severe cerebral palsy, bilateral blindness, or bilateral hearing
loss.
Statistical analysis
In a consensus meeting of the Netherlands Neonatology
Research Network a difference between the two treatment groups
on the composite motor score $7 points was considered clinically
relevant. To detect this on a 100 point scale, SD 26, alpha 0.05,
power 0.80, we planned to evaluate 434 infants. Accounting for
10% mortality and 20% incomplete follow-up, a total of 614
subjects needed to be included, i.e. 307 per group. Intentions to
treat analyses were performed.
We pre-specified two subgroups: birth weights #1000 g and
birth weights of .1000 g with high B/A ratios. We selected these
two birth weight groups because previous NICHD data showed an
increase in mortality of approximately 20% in infants with birth
weights # 1000 g who had received PT. [11]
Another subgroup analysis was performed to determine the
contrast between the two groups. Exploratory analyses were
performed of survivors and non-survivors.
We used the t test or Mann-Whitney test to compare continuous
variables and the chi-square test or Fisher exact test for categorical
variables. Repeatedly measured variables, such as TSB, albumin
and B/A ratio’s, were pooled for each infant; mean, maximum or
Bilirubin/Albumin Ratio Trial
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trough value’s were calculated for each infant and used for further
analyses. A two-sided P value of ,0.05 was considered statistically
significant. Statistical analyses were performed with SPSS 18.0
software for Windows (SPSS Inc, Chicago, IL).
We did not plan an interim analysis on the primary outcome
since these data would not be available before 18 to 24 months. An
independent data and safety monitoring committee reviewed
serious interim results, including death and other adverse
outcomes of prematurity, and the rate of exchange transfusions
after inclusion of 200 infants.
Results
Between April 2007 and April 2008, 615 (66%) out of 934
eligible infants were enrolled (Figure 1). On the whole, the B/A
ratio and TSB groups were similar with regards to the baseline
characteristics (Table 1).
Outcome at 18 to 24 months
Table 2 shows the neurodevelopmental outcome at 18 to 24
months’ corrected age for 478 children, i.e. 78% of the 615
randomized infants and 83% of the 573 children who survived
until neurodevelopmental testing (see also Table S1). The
primary outcome, i.e. the mean (6 SD) composite motor score
for the two groups was similar. The number of children with a
composite motor score of ,85 was also similar: 12 (5.1%) out of
237 in the B/A ratio group versus 9 (3.7%) out of 243 in the TSB
group (P= 0.51). We found no differences between the two groups
on the fine and gross motor scales, nor on the composite cognitive
scale. Moreover, the additional use of the B/A ratio did not reduce
the rate of NDI, severe or otherwise.
The two groups did not differ regarding TSB levels and B/A
ratios (Table 3) and the number and duration of PT sessions was
similar. Two infants in the B/A ratio group received an exchange
transfusion (one based on TSB, one based on TSB and B/A ratio
thresholds) against none in the TSB group.
The mean (6SD) albumin levels were 27.8 (65.5) versus 30.8
(64) for infants with birth weights of ,1250 g (n = 319) versus
$1250 g (n= 291), respectively.
Table 3 shows secondary outcomes during NICU hospitaliza-
tion. Fewer infants allocated to the B/A ratio group died during
the first two weeks. Although not statistically significant, the overall
mortality rate until discharge also appeared somewhat lower in the
B/A ratio versus the TSB group (RR, 0.64; 95% CI, 0.35 to 1.19;
Figure 1. Enrollment, randomization, and follow-up. At follow up there were no significant baseline differences between infants with known
and those with unknown neurodevelopmental status.
doi:10.1371/journal.pone.0099466.g001
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Table 1. Baseline characteristics at randomization.
Bilirubin/albumin ratio group Total serum bilirubin group
Characteristics n =306 n=309
Gestational age – wk 2962 2962
Birth weight – g 12646360 12506330
Small for gestational age – no.(%) 70 (23) 73 (24)
Male sex – no. (%) 171 (56) 181 (59)
Multiple birth – no.(%) 98 (32) 104 (34)
Race or ethnicity # – no./total no.(%)
- Caucasian 253/299 (83) 263/304 (85)
- Mediterranean 12/299 (4) 11/304 (4)
- Asian 10/299 (3) 14/304 (5)
- African 15/299 (5) 13/304 (4)
- Latin-American 9/299 (3) 3/304 (1)
Antenatal steroids - no./total no.(%) 257/290 (89) 246/295 (83)
Caesarean delivery – no./total no.(%) 139/304 (46) 138/297 (46)
5 min. Apgar score ,3 – no./total no.(%) 5/302 (2) 6/306 (2)
Positive Coombs test – no. (%) 1 (0.3) 1 (0.3)
Maternal irregular antibodies – no./total no.(%) 8/197 (4) 5/202 (2)
Plus-minus values are means 6 standard deviations. The denominator used to calculate the percentages of infants or mothers with a specific characteristic was the
number for whom the characteristic was known. This number was the total number in each group, unless otherwise specified. No significant differences were found
between the two groups. # Race or ethnicity was reported by patients’ parents or guardians or determined by the physician on reviewing the charts.
doi:10.1371/journal.pone.0099466.t001
Table 2. Outcomes at 18 to 24 months.
B/A ratio group TSB group P value# RR (95%CI) P value
$
Primary outcome
Composite motor score 100613 101612 0.49
- Fine motor scale 1163 12+3 0.28
- Gross motor scale 962 962 0.95
Composite cognitive score 101612 101611 0.61
Secondary outcome
Death 16/306 (5) 26/309 (8) 0.15 0.62 (0.34–1.14) 0.12
Severe neurodevelopmental impairment 10/264 (4) 5/269 (2) 0.20 2.04 (0.71–5.88) 0.19
Neurodevelopmental impairment 49/264 (19) 59/269 (22) 0.39 0.85 (0.60–1.19) 0.33
- Composite motor score ,70 4/237 (2) 2/243 (1) 0.44 2.05 (0.38–11.1) 0.40
- Composite motor score ,85 12/237 (5) 9/243 (4) 0.51 1.37 (0.59–3.18) 0.47
- Composite cognitive score ,70 4/256 (2) 0/264 (0) 0.06 9.28 (0.50–171) 0.13
- Composite cognitive score ,85 10/256 (4) 11/264 (4) 1.0 0.94 (0.41–2.17) 0.88
Cerebral palsy 8/264 (3) 4/269 (1) 0.26 2.04 (0.62–6.69) 0.24
Severe hearing loss 1/264 (,1) 1/269(,1) 1.0 1.02 (0.06–16.2) 0.99
Any hearing impairment 9/264 (3) 12/269 (5) 0.66 0.76 (0.33–1.78) 0.53
Severe visual impairment 0/264 (0) 1/269 (,1) 1.0 0.34 (0.014–8.3) 0.51
Any visual impairment 18/264 (7) 23/269 (9) 0.52 0.80 (0.44–1.44) 0.45
Plus-minus values are means 6 standard deviations. The denominator used to calculate the percentage of infants with a specific outcome was the number of infants
randomly assigned to each treatment group for whom that outcome was known at 18 to 24 months. This number was the total number in each group, unless otherwise
specified. The motor and cognitive scores were assessed with the BSID III (scores range from 50 to 150, where 150 indicates most advanced development).
The relative risk of each outcome was calculated for the BA ratio group as compared to the TSB group. In the B/A ratio group the mean (6SD) age at death was 30616
days and 1067 days in the TSB group. Severe NDI was a composite motor score of ,70, a composite cognitive score of ,70, moderate or severe cerebral palsy, severe
unilateral or bilateral hearing loss, or unilateral or bilateral blindness. Neurodevelopmental impairment was a composite motor score of ,85, a composite cognitive
score of ,85, any neurological impairment, any visual impairment, or hearing impairment.
P value#: Outcomes of t-test for continuous variables or Fischer exact test for categorical variables, two-tailed; RR is relative risk with (95% confidence interval). P value
$
: corresponding P value.
doi:10.1371/journal.pone.0099466.t002
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P=0.16). This prompted us to analyze mortality in these
subgroups in more detail.
Subgroup analyses according to birth weights (Table S2)
Among the 162 infants with birth weights #1000 g the
additional use of the B/A ratio did not reduce mortality. Among
the 453 infants with birth weights of .1000 g, mortality in the B/
A ratio group was significantly lower than in the TSB group (RR,
0.30; 95%CI: 0.10–0.92, P = 0.03).
The composite motor and cognitive scores were not affected by
treatment allocation in the two birth weight groups. The reduction
of approximately 10% in the composite outcome of death or NDI
in children with birth weights of .1000 g who were allocated to
the B/A ratio group was, therefore, attributed to the reduction in
mortality. Correspondingly, fewer adverse secondary outcomes,
e.g. sepsis, intraventricular hemorrhage, patent ductus arteriosus,
bronchopulmonary dysplasia, and necrotizing enterocolitis were
observed in this group, although the reduction in none of these
morbidities was statistically significant. Adverse secondary out-
comes tended to occur more frequently in the B/A ratio subgroup
of infants weighing #1000 g. The 18% increase in the incidence
of sepsis was statistically significant (RR, 1.5; 95% CI: 1.1–2.1,
P = 0.027).
Table S3 shows the results of the subgroup analysis regarding
treatment based on B/A ratio. In the B/A ratio group, 30% of the
infants received PT at least once on the basis of the B/A ratio and
not on the basis of the TSB level. In retrospect, 25% of the infants
in the TSB group had crossed the B/A ratio and not the TSB
threshold, but were by group definition not treated with PT.
Developmental outcomes did not differ between the two groups.
We found a tendency towards fewer mortalities in the B/A ratio
group: 7 (7.6%) out of 92 versus 13 (16.9%) out of 77 (RR, 0.45;
95% CI, 0.19 to 1.07, P= 0.09). Mortality was not reduced in the
B/A ratio subgroup of infants who were not treated on the basis of
the B/A ratio (RR, 0.75; 95% CI, 0.33 to 1.72, P= 0.52). Despite
comparable TSB and albumin levels, peak and mean B/A ratios
were significantly lower in the B/A ratio group, without any effect
on the total duration of PT.
On the other hand, almost half (48%) of all infants in the B/A
ratio group received PT at least once on the basis of the TSB level,
and not on the basis of the B/A ratio.
Relationship of bilirubin and outcome
Peak B/A ratios during the first ten days were .12% higher in
the non-survivors compared to the survivors (P = 0.004); peak TSB
levels and trough (6SD) albumin levels were significantly lower in
the non-survivors (Table S4).
Table 3. Bilirubin-related course and secondary outcomes during hospitalization.
B/A ratio group TSB group P value# RR (95%CI) P value
$
Neonatal course n=306 n=309
Peak TSB - mmol/l 179644 181646 0.66
Mean TSB - mmol/l 124635 127636 0.51
Trough albumin - g/L 25.565.2 25.465.2 0.76
Mean albumin – g/L 29.164.8 29.465.4 0.54
Peak B/A-ratio - mmol/g 6.261.4 6.361.7 0.41
Mean B/A-ratio - mmol/g 4.461.1 4.461.2 0.36
Phototherapy – no. (%) 270 (88%) 268 (87%) 0.63
Duration phototherapy - hrs 77651 71648 0.12
Exchange transfusions – no. 2 0 0.25
Secondary outcome n/n (%)
Death before day 15 4/306 (1.3) 17/309 (5.5) 0.006* 0.24 (0.08–0.70) 0.009*
Death before discharge 16/306 (5.2) 25/309 (8.1) 0.20 0.64 (0.35–1.19) 0.16
Sepsis 91/304 (30) 88/308 (29) 0.72 1.05 (0.82–1.34) 0.71
Meningitis 2/300 (0.7) 1/306 (0.3) 0.25 2.0 (0.19–22) 0.56
Intraventricular hemorrhage, grades 3 or 4 15/304 (5) 19/307 (6) 0.60 0.80 (0.41–1.54) 0.50
Patent ductus arteriosus 92/306 (30) 98/309 (32) 0.87 0.95 (0.75–1.20) 0.66
PDA treated with surgical ligation 15/306 (5) 17/309(6) 0.86 0.89 (0.45–1.75) 0.74
Necrotizing enterocolitis 28/306 (9) 31/309 (10) 0.79 0.91 (0.56–1.48) 0.71
NEC treated surgically 11/306 (4) 12/309 (4) 1.0 0.93 (0.41–2.10) 0.85
Periventricular leucomalacia, grades 3 or 4 2/304 (0.7) 1/307 (0.3) 0.25 2.02 (0.18–22) 0.57
Bronchopulmonary dysplasia at 36 wks’ postmenstrual age 26/306(9) 32/309 (10) 0.49 0.52 (0.50–1.34) 0.43
Retinopathy of prematurity grade 3 or higher 6/304 (2) 4/309 (1) 0.54 1.52 (0.43–5.35) 0.51
ALGO refer 14/269 (5) 16/270 (6) 0.85 0.88 (0.44–1.76) 0.72
Plus-minus values are means 6 standard deviations. The denominator used to calculate the percentage of infants with a specific outcome was the number for whom
the variable was known. This number was the total number in each group, unless otherwise specified. ALGO is automated auditory brainstem response. #: Outcome of
t-test for continuous variables or Fischer exact test for categorical variables, two-tailed; RR relative risk of the B/A ratio group in comparison to the TSB group with (95%
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The peak B/A ratios and TSB levels of the survivors without
hearing loss or with a composite motor score $85 were
comparable to the infants with any amount of hearing loss or a
composite motor score of ,85.
Discussion
In this multicenter trial we found no difference in the composite
motor score at 18 to 24 months’ corrected age between the infants
randomly allocated to receive PT and/or exchange transfusion
based on the additional use of the B/A ratio and the infants
allocated to receive treatment based exclusively on TSB levels.
Nor did we find differences in other clinical outcomes including
death. In pre-specified subgroup analyses mortality among the
infants with birth weights of .1000 g was significantly lower in
those allocated to the B/A ratio group, while mortality in both
subgroups of infants weighing #1000 g was similar. Furthermore,
we observed no significant differences in any of the bilirubin
parameters between the survivors with NDI, severe or otherwise,
or hearing loss and those without NDI or hearing loss.
The absence of any effect of the additional use of the B/A ratio
on infants’ neurological development including hearing loss or
mortality may be explained, at least partly, by similar TSB levels,
similar B/A ratios, and no significant differences in PT treatment.
In preterms, each of these variables is putatively involved in the
risk of bilirubin-associated NDI or death. [11,12] Considering the
occurrence of bilirubin encephalopathy in preterms with low TSB
levels the risk of developing bilirubin neurotoxicity is not
determined by TSB alone. [13–15] Only free bilirubin, and
perhaps the B/A ratio, are more closely associated with bilirubin
neurotoxicity. [2,5] Nevertheless, a correlation between peak TSB
levels and NDI or death was found in infants with extremely low
birth weights (ELBW). [9,16] This finding is in agreement with the
reduction in overall NDI at lower TSB levels in ELBW infants in
the ‘aggressive’ PT part of a recent randomized controlled trial
(RCT). [12] In this as well as in another RCT a trend was found
toward increased mortality in ELBW infants who had received
more PT. [11,12,17]
In our RCT fewer deaths in the B/A ratio subgroup of infants
with birth weights of .1000 g was not associated with less PT
(data not shown) or with any significant differences in neonatal
morbidities. The observed difference in mortality seemed biolog-
ically unrelated to the management of hyperbilirubinemia.
Moreover, this trial was not powered for mortality, and in
particular not for mortality in subgroups, therefore caution should
be exercised to interpret this finding, as it could be found by
change. The mortality rate in this subgroup, 1.8%, was also less
than the historical figure of approximately 6% kept by the Dutch
Perinatal Registry for infants who had also been treated according
to their TSB levels. Furthermore, the reduction in mortality
between the two categories of our trial appeared to be consistent.
We found a trend towards fewer deaths in the subgroup allocated
to the B/A ratio group who had been treated at least once on the
basis of their B/A ratios (29.3%, P=0.09) and who had
statistically significant lower (mean) peak B/A ratios.
We cannot explain why mortality was not reduced in the B/A
ratio subgroup with birth weights , 1000 g. We did not find
significant differences in causes of death between the two
treatment and birth weight categories, although there was a trend
towards fewer infants who had necrotizing enterocolitis in the B/A
ratio subgroup weighing.1000 g at birth (but not in the subgroup
, 1000 g). Infants in this subgroup lived significantly longer
compared to infants allocated to the TSB category (30616 versus
1067 days, P= 0.003). Overall, peak B/A ratios were significantly
higher in the non-survivors, whereas TSB and albumin levels were
actually lower. We do not know whether the infants who died had
a reduced anti-oxidant capacity due to lower albumin and
bilirubin levels. This finding supported our original hypothesis
that the additional use of the B/A ratio is a valuable parameter in
hyperbilirubinemia management in preterms. It is tempting to
speculate that it may be more appropriately to treat infants with
PT when bilirubin is more harmful and the infant brain is more
vulnerable to bilirubin neurotoxicity, i.e. when albumin levels are
low. The pathophysiological conditions may involve respiratory
and circulatory failure and sepsis, as was previously described. [18]
Oh et al. found that higher Bf levels are associated with a higher
risk of death or adverse neurodevelopmental outcome regardless of
clinical status, while in stable infants higher TSB levels were
associated with better outcomes. This finding also supports the
potential benefits of using the B/A ratio in addition to the TSB
level. It is a more useful indicator of the Bf level than using the
TSB level alone. [19,20] Using the B/A ratio in addition to TSB
levels may lead to reducing early mortality by a mechanism that is
as yet unknown. Our unexpected finding that use of the B/A ratio
in the management of preterms with birth weights of .1000 g
reduces mortality needs to be confirmed by a larger study.
The findings of the current study also underscore the efficacy of
phototherapy in managing hyperbilirubinemia in preterm infants:
only two babies in the entire cohort received an exchange
transfusion and none of the infants in the current cohort exhibited
neurological findings of classical kernicterus.
How can our results be translated into clinical practice?
Incorporating B/A ratios in management guidelines does not
seem an essential parameter to improve neurodevelopmental
outcome, but it may reduce mortality in infants weighing .1000 g
at birth. More specifically, the additional use of pre-defined B/A
ratios did not allow for earlier or more intensive treatment and
lower TSB levels. This was, at least in part, what we expected and
was related to its add-on use. Approximately half of all infants in
the B/A ratio group received PT at least once on the basis of the
TSB level crossing its threshold and not on the basis of the B/A
ratio, which would have resulted in unintentional undertreatment
when using the B/A ratio as the sole threshold for treatment
decision. We found no evidence for safe B/A ratio thresholds that
would justify the sole use of B/A ratio rather than TSB thresholds.
The contrast between the two treatment groups was thus diluted.
Higher pre-specified albumin levels and lower B/A ratios would
have resulted in more contrast, i.e. earlier treatment based on the
B/A ratio. Actually, the mean albumin levels were slightly higher
than the albumin levels that we used to predefine the BA ratio
threshold. Based on these relatively low differences, we anticipated
a rather small contrast. Another explanation for the absence of an
effect of the additional use of the B/A ratio on neurodevelop-
mental outcome could be the relatively low treatment thresholds:
the majority of preterms received PT. To date, the applied
thresholds were consensus–based. The results of our RCT
provided some evidence of the benefits without causing any harm.
We demonstrated that the additional use of the B/A ratio does not
result in harmful PT.
Conclusion
In preterm infants of 32 weeks’ gestation or less with
hyperbilirubinemia we found no significant effect of the additional
use of B/A ratio compared to TSB-based treatment on the
composite motor score at 18 to 24 months’ corrected age.
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